Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant completed the 52-week treatment period in Study M15-562 (NCT02985879)~* In the opinion of the investigator, the participant was compliant during participation in Study M15-562 (NCT02985879)~* Participant has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend)~Exclusion Criteria:~* Participants who weigh less than 44 kg (97 lbs) at the time of study entry~* Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI)~* Participant has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results~* More than 8 weeks have elapsed since the participant received his/her last dose of study drug in Study M15-562 (NCT02985879)~* Participant is considered by the investigator, for any reason, to be an unsuitable candidate to receive ABBV-8E12 or the participant is considered by the investigator to be unable or unlikely to comply with the dosing schedule or study evaluations

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg (Type: EXPERIMENTAL): Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
- M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg (Type: EXPERIMENTAL): Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
- M15-562 Placebo/M15-563 ABBV-8E12 2000 mg (Type: EXPERIMENTAL): Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
- M15-562 Placebo/M15-563 ABBV-8E12 4000 mg (Type: EXPERIMENTAL): Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Based on this trial design, predict the completion outcome and termination type (if applicable).